NN1177

O=C(NC(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)[C@@H](C)O)=O)CCCCNC(CC[C@H](NC(CC[C@@H](C(O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC(CC[C@H](NC(CC[C@H](NC(CCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)C(O)=O)=O)CO)=O)CCC(O)=O)=O)CO)=O)=O)C(O)=O)=O)=O)CC(C)C)=O)CC(C)C)=O)CC1=CNC2=CC=CC=C12)=O)CCC(N)=O)=O)C(C)C)=O)CC3=CC=CC=C3)=O)CCC(O)=O)=O)CCCNC(N)=N)=O)C)=O)CCCNC(N)=N)=O)CCCCN)=O)CO)=O)CCC(O)=O)=O)CC(C)C)=O)CC4=CC=C(O)C=C4)=O)CCCCN)=O)CO)=O)CC(C)C)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC5=CC=CC=C5)=O)[C@@H](C)O)=O)=O)CCC(N)=O)=O)(C)C)[C@@H](N)CC6=CNC=N6

[1]Simonsen L, et al. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. PLoS One. 2022 Mar 4;17 (3) :e0264974.|[2]Monfeuga T, et al. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. Mol Metab. 2023 Dec 7;79:101850.|[3]Säll C, et al. In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. Drug Metab Dispos. 2022 Jun 9:DMD-AR-2022-000865.